San Diego-centered Viking Therapeutics marked by itself as a significant competitor in the weight loss drug sector in February following revealing promising info from a mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection and in March the company unveiled